Wits University has begun its second coronavirus vaccine trial in South Africa. This phase will evaluate if the nano particle S-protein in the Covid-19 vaccine protects against the virus in adults aged 18 to 64. Speaking to the SABC, Wits professor of Vaccinology Shabir Madhi says Covid-19 vaccines being evaluated at an early stage in the country will generate evidence in the African context.